Market Survey on Age Related Vision Dysfunction Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment 2022 to 2033

<p>The global <strong>age-related vision dysfunction</strong><strong> </strong><strong>market</strong> garnered a market value of <strong>US$ 90 Billion</strong> in 2023 and is expected to accumulate a market value of <strong>US$ 130 Billion</strong> by registering a CAGR of <strong>3.7%</strong> in the forecast period 2022 to 2033.</p><table><tbody><tr><th scope='row'>Data Points</th><td>Key Statistics</td></tr><tr><th scope='row'>Expected Market Value (2023)</th><td>US$ 90 Billion</td></tr><tr><th scope='row'>Anticipated Forecast Value (2033)</th><td>US$ 130 Billion</td></tr><tr><th scope='row'>Projected Growth Rate (2023 to 2033)</th><td>3.7% CAGR</td></tr></tbody></table><p>Report Scope</p><table><tbody><tr><th scope='row'>Report Attribute</th><td>Details</td></tr><tr><th scope='row'>Market Value in 2023</th><td>US$ 90 Billion</td></tr><tr><th scope='row'>Market Value in 2033</th><td>US$ 130 Billion</td></tr><tr><th scope='row'>Growth Rate</th><td>CAGR of 3.7% from 2023 to 2033</td></tr><tr><th scope='row'>Base Year for Estimation</th><td>2022</td></tr><tr><th scope='row'>Historical Data</th><td>2018 to 2022</td></tr><tr><th scope='row'>Forecast Period</th><td>2023 to 2033</td></tr><tr><th scope='row'>Quantitative Units</th><td>Revenue in US Billion and CAGR from 2023 to 2033</td></tr><tr><th scope='row'>Report Coverage</th><td>Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis</td></tr><tr><th scope='row'>Segments Covered</th><td><ul><li>Dysfunction Type</li><li>Drug</li><li>Region</li></ul></td></tr><tr><th scope='row'>Regions Covered</th><td><ul><li>North America</li><li>Latin America</li><li>Europe</li><li>Asia Pacific</li><li>Middle East and Africa&nbsp;(MEA)</li></ul></td></tr><tr><th scope='row'>Key Countries Profiled</th><td><ul><li>The USA</li><li>Canada</li><li>Brazil</li><li>Mexico</li><li>Germany</li><li>The UK</li><li>France</li><li>Spain</li><li>Italy</li><li>China</li><li>Japan</li><li>South Korea</li><li>India</li><li>Malaysia</li><li>Singapore</li><li>Thailand</li><li>Indonesia</li><li>Australia</li><li>New Zealand</li><li>GCC</li><li>South Africa</li><li>Israel</li></ul></td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Aerie Pharmaceuticals</li><li>Santen Pharmaceutical</li><li>Sun Pharma Advanced Research Company Limited</li><li>Bausch + Lomb</li><li>D Western Therapeutics Institute</li><li>Novartis</li><li>AbbVie</li><li>Eyenovia</li><li>Orasis Pharmaceuticals</li><li>IVERIC Bio</li></ul></td></tr><tr><th scope='row'>Customization</th><td>Available Upon Request</td></tr></tbody></table>

<p>全球<em>年龄相关性视力功能障碍</em>市场在2023年实现了价值高达<em>900亿美元</em>的规模，预计在2022年至2033年的预测期内，通过实现<em>3.7%</em>的复合年增长率，将累计达到<em>1300亿美元</em>。</p><table><tbody><tr><th scope='row'>数据点</th><td>关键统计数据</td></tr><tr><th scope='row'>预期市场价值（2023年）</th><td>900亿美元</td></tr><tr><th scope='row'>预测市场价值（2033年）</th><td>1300亿美元</td></tr><tr><th scope='row'>预测增长率（2023年至2033年）</th><td>3.7% CAGR</td></tr></tbody></table><p>报告范围</p><table><tbody><tr><th scope='row'>报告属性</th><td>详细信息</td></tr><tr><th scope='row'>2023年市场价值</th><td>900亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>1300亿美元</td></tr><tr><th scope='row'>增长率</th><td>2023年至2033年间的3.7%复合年增长率</td></tr><tr><th scope='row'>估算基准年</th><td>2022年</td></tr><tr><th scope='row'>历史数据</th><td>2018年至2022年</td></tr><tr><th scope='row'>预测期</th><td>2023年至2033年</td></tr><tr><th scope='row'>量化单位</th><td>以亿美元计的收入和2023年至2033年的CAGR</td></tr><tr><th scope='row'>报告覆盖范围</th><td>收入预测、公司排名、竞争格局、增长因素、趋势和定价分析</td></tr><tr><th scope='row'>覆盖细分市场</th><td><ul><li>功能障碍类型</li><li>药物</li><li>地区</li></ul></td></tr><tr><th scope='row'>覆盖地区</th><td><ul><li>北美</li><li>拉丁美洲</li><li>欧洲</li><li>亚太地区</li><li>中东和非洲（MEA）</li></ul></td></tr><tr><th scope='row'>分析的关键国家</th><td><ul><li>美国</li><li>加拿大</li><li>巴西</li><li>墨西哥</li><li>德国</li><li>英国</li><li>法国</li><li>西班牙</li><li>意大利</li><li>中国</li><li>日本</li><li>韩国</li><li>印度</li><li>马来西亚</li><li>新加坡</li><li>泰国</li><li>印度尼西亚</li><li>澳大利亚</li><li>新西兰</li><li>GCC</li><li>南非</li><li>以色列</li></ul></td></tr><tr><th scope='row'>分析的关键公司</th><td><ul><li>Aerie Pharmaceuticals</li><li>Santen Pharmaceutical</li><li>Sun Pharma Advanced Research Company Limited</li><li>Bausch + Lomb</li><li>D Western Therapeutics Institute</li><li>Novartis</li><li>AbbVie</li><li>Eyenovia</li><li>Orasis Pharmaceuticals</li><li>IVERIC Bio</li></ul></td></tr><tr><th scope='row'>定制服务</th><td>可根据需求提供</td></tr></tbody></table>